Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials

Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Minyong, Jeong, Chang Wook, Kwak, Cheol, Ku, Ja Hyeon, Kim, Hyeon Hoe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601768/
https://www.ncbi.nlm.nih.gov/pubmed/28938672
http://dx.doi.org/10.18632/oncotarget.17741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601768/
https://www.ncbi.nlm.nih.gov/pubmed/28938672
http://dx.doi.org/10.18632/oncotarget.17741

Ejemplares similares